Bryn Mawr Capital Management LLC Increases Holdings in Eli Lilly and Company (NYSE:LLY)

Bryn Mawr Capital Management LLC boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 52.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,058 shares of the company’s stock after purchasing an additional 1,732 shares during the period. Bryn Mawr Capital Management LLC’s holdings in Eli Lilly and Company were worth $2,948,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in Eli Lilly and Company by 0.9% in the 3rd quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock valued at $37,908,273,000 after acquiring an additional 659,838 shares in the last quarter. Morgan Stanley lifted its position in Eli Lilly and Company by 0.7% in the 3rd quarter. Morgan Stanley now owns 12,545,572 shares of the company’s stock valued at $6,738,605,000 after acquiring an additional 83,915 shares in the last quarter. Northern Trust Corp lifted its position in Eli Lilly and Company by 3.6% in the 3rd quarter. Northern Trust Corp now owns 10,158,275 shares of the company’s stock valued at $5,456,314,000 after acquiring an additional 355,317 shares in the last quarter. International Assets Investment Management LLC lifted its holdings in shares of Eli Lilly and Company by 61,268.8% during the 4th quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock valued at $42,802,530,000 after buying an additional 7,330,815 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Eli Lilly and Company by 2.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 4,435,311 shares of the company’s stock valued at $2,382,339,000 after buying an additional 88,016 shares during the period. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock traded up $8.64 during trading on Friday, reaching $733.51. 1,998,801 shares of the stock traded hands, compared to its average volume of 3,021,320. The company has a market capitalization of $696.95 billion, a price-to-earnings ratio of 126.47, a P/E/G ratio of 1.60 and a beta of 0.34. Eli Lilly and Company has a 52-week low of $380.77 and a 52-week high of $800.78. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The business has a fifty day simple moving average of $761.79 and a two-hundred day simple moving average of $666.06.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.30 by $0.19. The company had revenue of $9.35 billion during the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm’s revenue was up 28.1% on a year-over-year basis. During the same quarter last year, the business posted $2.09 earnings per share. Sell-side analysts expect that Eli Lilly and Company will post 12.51 EPS for the current year.

Analyst Upgrades and Downgrades

LLY has been the topic of several research analyst reports. JPMorgan Chase & Co. increased their price target on Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a report on Friday, March 15th. Bank of America increased their price target on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a report on Friday, March 1st. DZ Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target on the stock. in a report on Wednesday, February 21st. Morgan Stanley increased their price target on Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a report on Friday, February 16th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $850.00 target price on shares of Eli Lilly and Company in a report on Friday, March 22nd. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $728.05.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the transaction, the insider now owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.